| Efficacy of lactoferrin in preventing recurrent urinary tract infections in pregnant Egyptian women: a randomized controlled trial 2025 · Lf group · Pregnant women aged 14–24 weeks’ gestation with a history of recurrent urinary tract infection | 200 mg | 120 days | 110 |
| Evaluation of Bovine Lactoferrin for Prevention of Late-Onset Sepsis in Low-Birth-Weight Infants: A Double-Blind Randomized Controlled Trial 2025 · 150 mg bLF (arm B) · Preterm infants born at 28 to 36 + 5 weeks’ gestational age and weighing 1000 g to <2500 g at birth, without sepsis at enrollment and tolerating oral feeds | 150 mg | 4 weeks | 102 |
| Evaluation of Bovine Lactoferrin for Prevention of Late-Onset Sepsis in Low-Birth-Weight Infants: A Double-Blind Randomized Controlled Trial 2025 · 300 mg bLF (arm C) · Preterm infants born at 28 to 36 + 5 weeks’ gestational age and weighing 1000 g to <2500 g at birth, without sepsis at enrollment and tolerating oral feeds | 300 mg | 4 weeks | 101 |
| Oral lactoferrin to prevent nosocomial sepsis and necrotizing enterocolitis of premature neonates and effect on T-regulatory cells 2014 · LF group · Premature infants who were very low birth weight or born before 32 weeks | 200 mg | — | 25 |
| The Preventive Effect of Lactoferrin-Containing Yogurt on Gastroenteritis in Nursery School Children-Intervention Study for 15 Weeks 2020 · LF group · Children aged 3–6 years attending nursery schools | 100 mg | 15 weeks | 661 |
| Bovine lactoferrin supplementation for prevention of necrotizing enterocolitis in very-low-birth-weight neonates: a randomized clinical trial 2014 · group LF · Very-low-birth-weight neonates (<1500 g at birth), born prematurely | 100 mg | 45 days | 247 |
| Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial 2009 · BLF alone · Very low-birth-weight infants (<1500 g) enrolled from birth; preterm neonates at risk of sepsis | 100 mg | 45 days | 153 |
| Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study 2006 · group C · Adults aged 19–84 years with Helicobacter pylori infection | 400 mg | 7 days | 134 |
| Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study 2006 · group B · Adults aged 19–84 years with Helicobacter pylori infection | 400 mg | 7 days | 132 |
| Effect of lactoferrin supplementation on the effectiveness and tolerability of a 7-day quadruple therapy after failure of a first attempt to cure Helicobacter pylori infection 2007 · group B · Adults with persistent Helicobacter pylori infection after failure of a first eradication treatment | 400 mg | 7 days | 34 |
| THE EFFECT OF ENTERAL LACTOFERRIN SUPPLEMENTATION IN PREVENTION OF MORBIDITY ASSOCIATED WITH IMMATURE DIGESTIVE TRACT IN PREMATURE INFANTS: PROSPECTIVE COHORT STUDY 2022 · lactoferrin group · Premature infants with gestational age ≤32 weeks, birth weight ≤1,500 g, and age ≤72 hours | 100 mg | 4 weeks | 27 |
| Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial 2012 · group A1 · Preterm very low birth weight neonates | 100 mg | 6 weeks | — |
| Effects of Lactoferrin on Prevention of Acute Gastrointestinal Symptoms in Winter: A Randomized, Double-Blinded, Placebo-Controlled Trial for Staff of Kindergartens and Nursery Schools in Japan 2020 · Low LF group · Healthy adults aged 20 years or older working at kindergartens or nursery schools in Nagano Prefecture, Japan | 200 mg | 12 weeks | 107 |
| Dietary effect of lactoferrin-enriched fermented milk on skin surface lipid and clinical improvement of acne vulgaris 2010 · lactoferrin group · Adults aged 18–30 with acne vulgaris | 200 mg | 12 weeks | 18 |
| Potent anti-obesity effect of enteric-coated lactoferrin: decrease in visceral fat accumulation in Japanese men and women with abdominal obesity after 8-week administration of enteric-coated lactoferrin tablets 2010 · eLF group · Japanese men and women aged 22–60 years with abdominal obesity (BMI >25 kg/m² and visceral fat area >100 cm²) | 300 mg | 8 weeks | — |
| The effect of lactoferrin supplementation on death or major morbidity in very low birthweight infants (LIFT): a multicentre, double-blind, randomised controlled trial 2020 · intervention group · Very low-birthweight infants born weighing less than 1500 g and aged less than 8 days | 200 mg/kg | — | 771 |
| Randomized Controlled Trial of Bovine Lactoferrin for Prevention of Sepsis and Neurodevelopment Impairment in Infants Weighing Less Than 2000 Grams 2020 · BLF group · Preterm infants weighing 500–2000 g at birth, enrolled in neonatal intensive care units within 72 hours after birth | 200 mg/kg | 8 weeks | 209 |
| Randomized controlled trial of lactoferrin for prevention of sepsis in peruvian neonates less than 2500 g 2015 · lactoferrin group · Neonates with birth weights of 500–2500 g, born in or referred to neonatal units within the first 72 hours of life | 200 mg/kg | 4 weeks | 95 |
| Randomized Controlled Trial of Talactoferrin Oral Solution in Preterm Infants 2016 · TLf · Preterm infants with birth weights of 750–1500 g | 300 mg/kg | 4 weeks | 60 |
| Preventing Sepsis in Preterm Infants with Bovine Lactoferrin: A Randomized Trial Exploring Immune and Antioxidant Effects 2025 · bLf · Preterm infants with very low birth weight (≤1500 g) and/or gestational age ≤32 weeks, randomized before 72 hours of age | 150 mg/kg | 4 weeks | 50 |
| Inhibition of intestinal polyp growth by oral ingestion of bovine lactoferrin and immune cells in the large intestine 2014 · 1.5 g bLF group · Adults with adenomatous colorectal polyps; age range and sex not reported | 1.5 g | 1 year | 37 |
| Inhibition of intestinal polyp growth by oral ingestion of bovine lactoferrin and immune cells in the large intestine 2014 · 3.0 g bLF group · Adults with adenomatous colorectal polyps; age range and sex not reported | 3 g | 1 year | 32 |
| Impact of lactoferrin supplementation on growth and prevalence of Giardia colonization in children 2008 · lactoferrin · Previously weaned children aged 12–36 months in Lima, Peru | 1 g | 270 days | 26 |
| Phase IB trial of oral talactoferrin in the treatment of patients with metastatic solid tumors 2010 · 4.5 g/day talactoferrin · Adults with metastatic solid tumors who had progressed on, or were ineligible for, standard chemotherapy | 4.5 g | — | — |
| Phase IB trial of oral talactoferrin in the treatment of patients with metastatic solid tumors 2010 · 9 g/day talactoferrin · Adults with metastatic solid tumors who had progressed on, or were ineligible for, standard chemotherapy | 9 g | — | — |
| Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy 2011 · oral talactoferrin · Adults with stage IIIB to IV non-small-cell lung cancer whose disease progressed after one or two prior lines of systemic anticancer therapy | 3 g | 42 weeks | — |
| A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis 2013 · talactoferrin group · adults with severe sepsis | 4.5 g | 4 weeks | — |
| Effects of Lactoferrin on Prevention of Acute Gastrointestinal Symptoms in Winter: A Randomized, Double-Blinded, Placebo-Controlled Trial for Staff of Kindergartens and Nursery Schools in Japan 2020 · High LF group · Healthy adults aged 20 years or older working at kindergartens or nursery schools in Nagano Prefecture, Japan | 600 mg | 12 weeks | 112 |
| Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study 2000 · 600 mg lactoferrin group · Adults with mild or moderate tinea pedis | 600 mg | 8 weeks | — |
| The Lacuna Trial: a double-blind randomized controlled pilot trial of lactoferrin supplementation in the very preterm infant 2016 · bovine lactoferrin group · Very preterm infants born before 31 weeks gestation | 100 mg | — | — |
| Effects of Lactoferrin on Oral and Throat Conditions under Low Humidity Environments: A Randomized, Double-Blind, and Placebo-Controlled Crossover Trial 2023 · bLF treatment · Healthy adults aged 18–65 years | 96.3 mg | 1 day | — |
| Influence of bovine lactoferrin on feeding intolerance and intestinal permeability in preterm infants: a randomized controlled trial 2024 · lactoferrin group · Preterm infants aged 26–34 weeks gestational age with feeding intolerance | 100 mg | 4 weeks | — |
| Bovine lactoferrin supplementation for prevention of necrotizing enterocolitis in very-low-birth-weight neonates: a randomized clinical trial 2014 · group BLF + LGG · Very-low-birth-weight neonates (<1500 g at birth), born prematurely | 100 mg | 45 days | 238 |
| Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial 2009 · BLF plus LGG · Very low-birth-weight infants (<1500 g) enrolled from birth; preterm neonates at risk of sepsis | 100 mg | 45 days | 151 |
| Bovine lactoferrin prevents invasive fungal infections in very low birth weight infants: a randomized controlled trial 2012 · group A2 · Preterm very low birth weight neonates | 100 mg | 6 weeks | — |
| Effects of a Bovine Lactoferrin Formulation from Cow's Milk on Menstrual Distress in Volunteers: A Randomized, Crossover Study 2016 · FeLf · Healthy women aged 20–49 with regular menstrual cycles and pain during menstruation | 124 mg | — | 35 |
| Oral administration of bovine lactoferrin for treatment of tinea pedis. A placebo-controlled, double-blind study 2000 · 2000 mg lactoferrin group · Adults with mild or moderate tinea pedis | 2 g | 8 weeks | — |
| Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance 2017 · Group A · Adults with chronic hepatitis C receiving pegylated interferon-α-2b and ribavirin | 70.8 g | 1 year | 30 |
| Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon-α-2b and Ribavirin Reduces Sleep Disturbance 2017 · Group B · Adults with chronic hepatitis C receiving pegylated interferon-α-2b and ribavirin | 70.8 g | 1 year | 30 |
| Effect of tablets containing lactoferrin and lactoperoxidase on gingival health in adults: A randomized, double-blind, placebo-controlled clinical trial 2019 · high-dose tablets · healthy adults | 60 mg | 12 weeks | — |
| Effect of tablets containing lactoferrin and lactoperoxidase on gingival health in adults: A randomized, double-blind, placebo-controlled clinical trial 2019 · low-dose tablets · healthy adults | 20 mg | 12 weeks | — |
| A Patented Dietary Supplement (Hydroxy-Methyl-Butyrate, Carnosine, Magnesium, Butyrate, Lactoferrin) Is a Promising Therapeutic Target for Age-Related Sarcopenia through the Regulation of Gut Permeability: A Randomized Controlled Trial 2024 · experimental formula · Adults aged 55–85 with sarcopenia | 100 mg | 120 days | 30 |
| Efficacy and tolerability of oral bovine lactoferrin compared to ferrous sulfate in pregnant women with iron deficiency anemia: a prospective controlled randomized study 2009 · Group A · Pregnant women with iron deficiency anemia | 200 mg | 30 days | 49 |
| A Randomized, Double-Blind, Controlled Trial to Assess the Effects of Lactoferrin at Two Doses vs. Active Control on Immunological and Safety Parameters in Healthy Adults 2025 · low-dose rhLF · Healthy men and premenopausal women aged 18–45 years | 340 mg | 4 weeks | 21 |
| Bioavailability of a Novel Form of Microencapsulated Bovine Lactoferrin and Its Effect on Inflammatory Markers and the Gut Microbiome: A Pilot Study 2018 · Product A (standard bLF), 200 mg dose · Healthy men aged 18–65 years | 200 mg | 4 weeks | 6 |
| Bioavailability of a Novel Form of Microencapsulated Bovine Lactoferrin and Its Effect on Inflammatory Markers and the Gut Microbiome: A Pilot Study 2018 · Product B (Inferrin), 200 mg dose · Healthy men aged 18–65 years | 200 mg | 4 weeks | 6 |
| Lactoferrin efficacy versus ferrous sulfate in curing iron disorders in pregnant and non-pregnant women 2010 · Arm A (pregnant women) · Pregnant women of child-bearing age suffering from iron deficiency or iron-deficiency anemia | 200 mg | — | — |
| Lactoferrin efficacy versus ferrous sulfate in curing iron disorders in pregnant and non-pregnant women 2010 · Arm A (non-pregnant women) · Non-pregnant women of child-bearing age suffering from iron deficiency or iron-deficiency anemia | 200 mg | — | — |
| Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study 2010 · lactoferrin · Advanced-stage cancer patients with anemia undergoing chemotherapy | 200 mg | 12 weeks | — |
| Lactoferrin versus ferrous sulphate for the treatment of iron deficiency anemia during pregnancy: a randomized clinical trial 2016 · lactoferrin · Pregnant women in the second trimester with iron deficiency anemia | 250 mg | 8 weeks | — |
| Lactoferrin plus health education versus total dose infusion (TDI) of low-molecular weight (LMW) iron dextran for treating iron deficiency anemia (IDA) in pregnancy: a randomized controlled trial 2019 · Group A · Pregnant women in the second or third trimester with iron deficiency anemia | 200 mg | 4 weeks | — |
| Lactoferrin for iron-deficiency anemia in children with inflammatory bowel disease: a clinical trial 2022 · Lactoferrin group · Children aged 5–18 years with inflammatory bowel disease in remission and iron-deficiency anemia | 100 mg | 90 days | 40 |
| Bovine lactoferrin is effective to suppress Helicobacter pylori colonization in the human stomach: a randomized, double-blind, placebo-controlled study 2005 · bLF group · Healthy adults positive for H. pylori infection | 400 mg | 12 weeks | 31 |
| Oral lactoferrin as a treatment of pediatrics' anemia resulted from chronic kidney diseases: a randomized controlled trial 2025 · Group 1 (lactoferrin group) · Children and adolescents under 18 years with stage 3–5 chronic kidney disease and anemia; all participants were receiving erythropoietin. | 100 mg | 90 days | 30 |
| Bioavailability of a Novel Form of Microencapsulated Bovine Lactoferrin and Its Effect on Inflammatory Markers and the Gut Microbiome: A Pilot Study 2018 · Product A (standard bLF), 600 mg dose · Healthy men aged 18–65 years | 600 mg | 4 weeks | 6 |
| Bioavailability of a Novel Form of Microencapsulated Bovine Lactoferrin and Its Effect on Inflammatory Markers and the Gut Microbiome: A Pilot Study 2018 · Product B (Inferrin), 600 mg dose · Healthy men aged 18–65 years | 600 mg | 4 weeks | 6 |
| A Randomized, Double-Blind, Controlled Trial to Assess the Effects of Lactoferrin at Two Doses vs. Active Control on Immunological and Safety Parameters in Healthy Adults 2025 · bLF · Healthy men and premenopausal women aged 18–45 years | 3.4 g | 4 weeks | 23 |
| A Randomized, Double-Blind, Controlled Trial to Assess the Effects of Lactoferrin at Two Doses vs. Active Control on Immunological and Safety Parameters in Healthy Adults 2025 · high-dose rhLF · Healthy men and premenopausal women aged 18–45 years | 3.4 g | 4 weeks | 22 |
| Lactoferrin regulates the immune responses in post-surgical patients 2001 · LF-treated patients · Women and men, mean age 50 years, undergoing thyroid surgery | 20 mg | 5 days | 18 |
| Bovine Lactoferrin Enhances TLR7-Mediated Responses in Plasmacytoid Dendritic Cells in Elderly Women: Results From a Nutritional Intervention Study With Bovine Lactoferrin, GOS and Vitamin D 2018 · Intervention group, first 3 weeks (bLF only) · Women aged 65–85 who were generally healthy | 1 g | 3 weeks | 15 |
| Mechanisms affecting the gut of preterm infants in enteral feeding trials: a nested cohort within a randomised controlled trial of lactoferrin 2023 · Lactoferrin · Preterm infants born at less than 32 weeks’ gestation | 150 mg/kg | — | — |
| Lactoferrin: A Promising New Player in Treatment of Iron Deficiency Anemia in Patients on Regular Hemodialysis: A Randomized Controlled Trial 2023 · BLF group · Patients on regular hemodialysis with iron deficiency anemia | 200 mg | 26 weeks | 70 |
| A randomized, double-blind, crossover, placebo-controlled clinical trial to assess effects of the single ingestion of a tablet containing lactoferrin, lactoperoxidase, and glucose oxidase on oral malodor 2016 · Test tablet · Adults aged 20–65 with mouth-air volatile sulfur compound concentrations above the olfactory threshold; healthy adults without the listed severe diseases | 20 mg | 1 day | 39 |
| Bovine Lactoferrin Enhances TLR7-Mediated Responses in Plasmacytoid Dendritic Cells in Elderly Women: Results From a Nutritional Intervention Study With Bovine Lactoferrin, GOS and Vitamin D 2018 · Intervention group, weeks 4–6 (bLF + GOS) · Women aged 65–85 who were generally healthy | 1 g | 3 weeks | 15 |
| Bovine Lactoferrin Enhances TLR7-Mediated Responses in Plasmacytoid Dendritic Cells in Elderly Women: Results From a Nutritional Intervention Study With Bovine Lactoferrin, GOS and Vitamin D 2018 · Intervention group, weeks 7–9 (bLF + GOS + vitamin D) · Women aged 65–85 who were generally healthy | 1 g | 3 weeks | 15 |
| Effects of Long-Term Supplementation of Bovine Colostrum on Iron Homeostasis, Oxidative Stress, and Inflammation in Female Athletes: A Placebo-Controlled Clinical Trial 2022 · colostrum group · Female youth basketball players competing in first and extra-class leagues; ages not stated | 60 mg | 24 weeks | 11 |
| Inflammatory responses improve with milk ribonuclease-enriched lactoferrin supplementation in postmenopausal women 2010 · R-ELF group · Healthy postmenopausal women aged 45–60 years | 250 mg | 26 weeks | — |
| Supplementation With Lactoferrin and Lysozyme Ameliorates Environmental Enteric Dysfunction: A Double-Blind, Randomized, Placebo-Controlled Trial 2019 · experimental group · Children aged 12–23 months in rural Malawi | 1.5 g | 16 weeks | — |